InvestorsHub Logo
Followers 594
Posts 20577
Boards Moderated 0
Alias Born 02/01/2012

Re: dr_lowenstein post# 33192

Sunday, 10/04/2015 2:53:53 PM

Sunday, October 04, 2015 2:53:53 PM

Post# of 48316
Too funny. On the contrary $ONCS EP+IL12 save lives where before there was no hope. Merck and UCSF, as Collaborators, have made the decision that $ONCS EP+IL12 combination with Keytruda is most worthy to increase ORR vs Keytruda alone and are sponsoring a 41 person Clinical trial.

https://clinicaltrials.gov/ct2/show/NCT02493361?term=UCSF+and+keytruda&rank=2

MRK competitor BMS continues to increase lead with Opdivo and Yervoy.